GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » E10

Aevi Genomic Medicine (Aevi Genomic Medicine) E10 : $-1.31 (As of Sep. 2019)


View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aevi Genomic Medicine's adjusted earnings per share data for the three months ended in Sep. 2019 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.31 for the trailing ten years ended in Sep. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-28), Aevi Genomic Medicine's current stock price is $0.1659. Aevi Genomic Medicine's E10 for the quarter that ended in Sep. 2019 was $-1.31. Aevi Genomic Medicine's Shiller PE Ratio of today is .


Aevi Genomic Medicine E10 Historical Data

The historical data trend for Aevi Genomic Medicine's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine E10 Chart

Aevi Genomic Medicine Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aevi Genomic Medicine Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1.30 -1.31

Competitive Comparison of Aevi Genomic Medicine's E10

For the Biotechnology subindustry, Aevi Genomic Medicine's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aevi Genomic Medicine's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's Shiller PE Ratio falls into.



Aevi Genomic Medicine E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aevi Genomic Medicine's adjusted earnings per share data for the three months ended in Sep. 2019 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.06/108.3294*108.3294
=-0.060

Current CPI (Sep. 2019) = 108.3294.

Aevi Genomic Medicine Quarterly Data

per share eps CPI Adj_EPS
200912 -2.060 91.111 -2.449
201003 0.275 91.821 0.324
201006 -0.472 91.962 -0.556
201009 -0.800 92.162 -0.940
201012 -0.160 92.474 -0.187
201103 -0.063 94.283 -0.072
201106 -0.260 95.235 -0.296
201109 -0.350 95.727 -0.396
201112 -0.200 95.213 -0.228
201203 -0.280 96.783 -0.313
201206 -0.690 96.819 -0.772
201209 -0.250 97.633 -0.277
201212 -0.170 96.871 -0.190
201303 -0.290 98.209 -0.320
201306 -0.110 98.518 -0.121
201309 -0.330 98.790 -0.362
201312 -0.380 98.326 -0.419
201403 -0.280 99.695 -0.304
201406 -0.210 100.560 -0.226
201409 -0.210 100.428 -0.227
201412 -0.320 99.070 -0.350
201503 -0.360 99.621 -0.391
201506 -0.280 100.684 -0.301
201509 -0.660 100.392 -0.712
201512 -0.150 99.792 -0.163
201603 -0.340 100.470 -0.367
201606 -0.350 101.688 -0.373
201609 -0.290 101.861 -0.308
201612 -0.220 101.863 -0.234
201703 -0.290 102.862 -0.305
201706 -0.220 103.349 -0.231
201709 -0.230 104.136 -0.239
201712 -0.090 104.011 -0.094
201803 -0.150 105.290 -0.154
201806 -0.140 106.317 -0.143
201809 -0.120 106.507 -0.122
201812 -0.100 105.998 -0.102
201903 -0.070 107.251 -0.071
201906 -0.060 108.070 -0.060
201909 -0.060 108.329 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.


Aevi Genomic Medicine  (NAS:GNMX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aevi Genomic Medicine E10 Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Executives
Michael F Cola director, officer: Chief Executive Officer 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil officer: Chief Scientific Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca 10 percent owner 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper officer: CFO & Corporate Secretary C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum officer: Chief Legal Officer C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman officer: Chief Financial Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio officer: Chief Operating Officer 435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087